McKenna's Pharmacology for Nursing, 2e

970

Index

Anaesthetic agents continued drug–drug interactions, 427 pharmacokinetics, 426 therapeutic actions and indications, 426 older adults, 417 Anagrelide, 755, 758, 758 Anakinra, 253–255, 264, 266 Analgesic, 240, 241 Anaphylactic reaction, 33, 34 Anaplasia, 190

Anthelmintic agents, 179–188 adults, 183 adverse effects, 186 care considerations, 186–187 children, 183

automaticity, 697 conductivity, 697 haemodynamics, 697–698 types, 698–699 care considerations, 708–709 children, 701 chronic antiarrhythmic therapy, managing, 709–711 class I, 702–704 adverse effects, 704 contraindications and cautions, 702, 704 drug–drug interactions, 704 pharmacokinetics, 702 therapeutic actions and indications, 702 class II, 703, 704–705 adverse effects, 705 contraindications and cautions, 705 drug–drug interactions, 705 pharmacokinetics, 705 therapeutic actions and indications, 704–705 class III, 703, 706 adverse effects, 706 contraindications and cautions, 706 drug–drug interactions, 706 pharmacokinetics, 706 therapeutic actions and indications, 706 class IV, 703, 706–707 adverse effects, 707 contraindications and cautions, 707 drug–drug interactions, 707 pharmacokinetics, 707 therapeutic actions and indications, 706 older adults, 701 proarrhythmic, 696, 701 Antiarthritis agents, 240, 252–255 care considerations, 255 disease-modifying antirheumatic drugs, 253–255 gold compounds, 252–253 Antiasthmatics. See Bronchodilators/ antiasthmatics Antibiotics, 90–123 adults, 93 adverse effects, 87 aminoglycosides, 90, 95–97 adverse effects, 96 care considerations, 96–97 contraindications and cautions, 95–96 drug–drug interactions, 96 pharmacokinetics, 95 therapeutic actions and indications, 95 antimycobacterials. See Antimycobacterials antineoplastic, 205–208 adverse effects, 207 care considerations, 208 contraindications and cautions, 207 drug–drug interactions, 207 pharmacokinetics, 207 therapeutic actions and indications, 205

contraindications and cautions, 186 critical thinking scenario, 184–185 drug–drug interactions, 186 helminths, 179, 180 intestine-invading worm infections, 180–181 Ascaris , 179, 180, 181 cestodes, 179, 180, 181 hookworm infections, 179, 180, 181 nematodes, 179, 180 pinworm infections, 179, 180 platyhelminths (flatworms), 179, 181 threadworm infestation, 180, 181 whipworm infections, 179, 180, 181 older adults, 183 pharmacokinetics, 185–186 therapeutic action and indications, 185 tissue-invading worm infections, 181–182 filariasis, 179, 181 schistosomiasis, 179, 181–182 trichinosis, 179, 181 Anthrax, 106, 107, 282 Anti Rh(D) immunoglobin, 286 Antianginal agents, 713–726 adults, 717 beta-adrenergic blockers, 716, 722–723 adverse effects, 723 care considerations, 723 contraindications and cautions, 723 drug–drug interactions, 723 pharmacokinetics, 722–723 therapeutic actions and indications, 722 calcium channel blockers, 714, 716, 724–725 adverse effects, 724 care considerations, 725 contraindications and cautions, 724 drug–drug interactions, 724–725 pharmacokinetics, 724 therapeutic actions and indications, 724 children, 717 coronary artery disease (CAD), 713, 714–715, 730–731 nitrates, 713, 714, 716, 717–720 adverse effects, 718–719 care considerations, 719–720 contraindications and cautions, 718 drug–drug interactions, 719 pharmacokinetics, 718 therapeutic actions and indications, 717–718 older adults, 717 potassium channel openers, 714, 716, 825–726 Antiarrhythmic agents, 696–711 adults, 701 antiarrhythmics, 696, 701 arrhythmias, 697–701

Anastrazole, 212, 213 Andostenedione, 962 Androgens, 627, 628–631 adverse effects, 630

androgenic effects, 627, 630 care considerations, 630–631

contraindications and cautions, 630 drug–laboratory test interferences, 630 pharmacokinetics, 629 therapeutic actions and indications, 629 Angelica, 962 Angina, 715 antianginal agents. See Antianginal agents handling an attack, 720–722 Angina pectoris, 713, 715 Angiogenesis, 190, 191 Angiotensin-converting-enzyme (ACE) inhibitors, 657, 662–665, 668–669 adverse effects, 668 care considerations, 668–669 contraindications and cautions, 668 drug–drug interactions, 668 drug–food interactions, 668 pharmacokinetics, 668 therapeutic actions and indications, 662–663 Angiotensin II-receptor blockers, 665, 669–671 adverse effects, 669–670 angiotensin II-receptor, 657, 669 care considerations, 670–671 contraindications and indications, 669 drug–drug interactions, 670 pharmacokinetics, 669 therapeutic actions and indications, 669 Anidulafungin, 152, 154–155 Anise, 962 Anopheles mosquito, 163, 164–165 Antacids, 896, 900, 904–906 adverse effects, 905 care considerations, 905–906 contraindications and cautions, 905 drug–drug interactions, 905 pharmacokinetics, 905 therapeutic actions and indications, 904–905 Antagonists, 15, 17 Anterior pituitary, 512, 515, 516 hormones, drugs affecting, 521, 525–530 growth hormone agonists. See Growth hormone agonists growth hormone antagonists. See Growth hormone antagonists